Health Economics›Colorectal cancer›Adjuvant therapy

Adjuvant therapy

Colorectal cancer · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Tegafur, Uracil, Folinic acid Variant #01 Partial	—	R 11 824	35d	—	—	~5	~R 59 119 indirect	—
FULV Variant #29	—	R 3 601	14d	~6.2 mo	~13.2 mo	~2	~R 7 201 PFS proxy · indirect	6
CapeOx Variant #01	—	R 2 620	21d	~6.7 mo	~19.9 mo	~2	~R 5 240 PFS proxy · indirect	3
mFOLFOX6 Variant #02	—	R 2 617	14d	~9.5 mo	~23.3 mo	~12	~R 31 399 PFS proxy · indirect	9
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 2 054	14d	—	~20.7 mo	~3	~R 6 161 PFS proxy · indirect	2
Capecitabine monotherapy Variant #01	—	R 1 039	21d	~5.7 mo	—	~8	~R 8 309 PFS proxy · indirect	5
FULV (L-Leucovorin) Variant #06 Partial	—	R 61	14d	—	~6.1 mo	~30	~R 1 820 PFS proxy · indirect	1
Observation Partial	—	—	—	~3.4 mo	—	—	—	2

8 of 8 regimens shown